Drug Pricing and Medicaid Rebate Reporting: Enforcement Risk Remains
A recent analysis examines ongoing enforcement risks tied to drug pricing and Medicaid rebate reporting under the Medicaid Drug Rebate Program (MDRP), focusing on a federal court decision addressing how “strength” should be defined for products with the same concentration but different volumes. The court adopted a broader FDA-based definition and dismissed False Claims Act allegations, but the absence of clear statutory or regulatory guidance leaves room for continued scrutiny and potential shifts in agency interpretation. Read the full article for key takeaways on how courts may approach undefined MDRP terms, how FDA regulations can influence rebate reporting obligations, and practical steps manufacturers can take to mitigate False Claims Act risk through consistent, well documented compliance practices.
This article originally appeared in Reuters Legal News.
This post is as of the posting date stated above. Sidley Austin LLP assumes no duty to update this post or post about any subsequent developments having a bearing on this post.
You might also like
DOJ Announces Accelerated Review of FCA Qui Tams Alleging Fraud Against State-Administered Benefits Programs It is not business as usual at DOJ. In the latest announcement related to the Department’s efforts to fight alleged fraud, on May 27, 2026, Assistant Attorney General Brett Shumate issued a memorandum directing DOJ’s Civil Division and U.S. Attorneys’ Offices to accelerate the review of qui tams alleging fraud against federally funded state-administered benefits programs, including programs involving housing, food assistance, medical care, and cash assistance. The memorandum, titled “Accelerating Review and Enhancing Enforcement in Benefits Fraud Matters,” implements President Trump’s March 2026 Executive Order establishing the “Task Force to Eliminate Fraud,” which we reported on here, and which directed the Department to take appropriate action to promote “meritorious” qui tams and to complete investigations sooner, including within the 60-day statutory period.
As with other recent announcements on FCA enforcement, including related to the FOCUS Initiative, this latest move reflects both DOJ’s increasing emphasis on whistleblower-driven FCA enforcement as well as its commitment to preserve its own resources, including through the exercise of its statutory right to dismiss qui tams in appropriate circumstances. It is also consistent with the Administration’s recent focus on increasing enforcement against fraud directed at certain federally-funded state benefit programs, as we reported here.
Faster Qui Tam Vetting; More Relator-Led Litigation
The memorandum directs DOJ attorneys to complete review of new benefits fraud qui tam complaints “to the maximum extent practicable” within the FCA’s initial 60-day seal period and no later than 120 days. After that review, DOJ is instructed either to:
- permit the relator to proceed with the action;
- continue investigating the allegations; or
- seek dismissal of complaints “because the allegations lack adequate specificity or are legally deficient.”
DOJ acknowledges that the policy “will increase the number of benefits fraud matters primarily litigated by relators.” Cases that fall into this bucket include those where:
- the alleged conduct clearly states an FCA violation;
- the allegations are corroborated by agency information, data analytics, or insider knowledge;
- the scheme is not novel or complex;
- potential damages are below $10 million; and
- aggravating circumstances exist, such as beneficiary harm, concealment, or ongoing misuse of federal funds.
Relators and their counsel will be expected to litigate these cases with minimal burden on the government, while DOJ will continue exercising oversight authority throughout the litigation.
DOJ also states that this process is intended to conserve government resources by allowing relators to litigate less complex matters while DOJ focuses on “the largest, most complex, and harmful fraud schemes,” which will largely fall within the “needs more investigation” bucket. This division of labor is perhaps slightly in tension with statements made by Assistant Attorney General Colin McDonald, who, during his swearing-in ceremony to lead the new National Fraud Detection Center, stated: “No longer will [DOJ] be uninterested in low levels of fraud; we will be interested in all of it.”
While the Department’s commitment to expediting the vetting of qui tams is laudable, it represents a seismic shift and remains to be seen whether Civil Frauds and the U.S. Attorney’s Offices have the resources and bandwidth to make good on the promise, or whether the lion’s share of the cases simply default to further investigation.
Expedited Investigation Procedures
For matters DOJ elects to investigate further, the memorandum establishes an accelerated investigative framework built around a presumptive 120-day investigative period.
Among other things, DOJ attorneys are instructed to:
- issue subpoenas and CIDs promptly;
- conduct early witness interviews;
- use targeted information requests;
- enforce CID deadlines aggressively, including by moving in court if necessary; and
- consider relying on relators’ counsel to assist investigations.
The memorandum further encourages DOJ attorneys to make intervention decisions before damages analyses are fully developed where liability evidence is sufficiently strong, and to pursue the evidence of damages during discovery.
Coordinated Civil, Criminal, and Administrative Enforcement
Notably, the language in DOJ’s memo and release announcing this accelerated review of qui tams signals that close coordination will be occurring to ensure that a “whole of government” approach will be used, placing all (i.e., administrative, civil, and criminal) enforcement options on the table.
New matters are to be referred promptly to DOJ’s Criminal Division and National Fraud Enforcement Division (NFED) for evaluation of potential criminal exposure.
Affected agencies also will evaluate possible administrative remedies, including payment suspensions, while DOJ intends to rely increasingly on agency data analytics and program information to corroborate whistleblower allegations.
Key Takeaways
The memorandum reflects several broader trends in DOJ FCA enforcement.
First, DOJ continues to emphasize speed in FCA investigations and intervention decisions, particularly in areas identified as Administration priorities. The memorandum’s rigid timelines may create significant pressure on defendants early in investigations.
Second, the memorandum signals DOJ’s willingness to rely more heavily on relators and private counsel to litigate FCA cases involving less complex benefits fraud allegations. That approach may increase the volume of FCA litigation in areas involving Medicaid, housing assistance, food assistance, and other state-administered benefits programs.
Third, the memorandum reinforces DOJ’s increasing use of coordinated enforcement mechanisms across civil, criminal, and administrative channels. Defendants facing benefits fraud allegations may therefore encounter simultaneous exposure to FCA damages and penalties, criminal investigation, payment suspensions, and agency enforcement actions. This news, combined with the advent of anticipated increased resourcing and personnel for NFED, means that we should potentially expect an uptick in criminal investigations and case openings based on referrals, regardless of whether such referrals ultimately yield charges.
Finally, the memorandum underscores DOJ’s continued emphasis on data analytics and interagency coordination in identifying and developing FCA matters. Organizations participating in federally funded benefits programs should expect heightened scrutiny of billing practices, eligibility determinations, certifications, and program compliance controls.
Civil EnforcementDOJEnforcementFalse Claims Act
DOJ and Texas AG Announce First Settlement in National Investigation of Gender-Affirming Care for Minors On May 15, 2026, the U.S. Department of Justice (“DOJ”) and Texas Attorney General Ken Paxton announced agreements with Texas Children’s Hospital (“TCH”) resolving allegations related to TCH’s provision of gender-affirming care to minors. The matter marks the first publicly announced resolution arising from DOJ’s ongoing nationwide investigation into alleged federal-law violations associated with such care. The resolution is notable not only because of the subject matter involved, but also because of the enforcement architecture it reflects: coordination between DOJ and a state attorney general; reliance on False Claims Act (“FCA”) and Federal Food, Drug, and Cosmetic Act (“FDCA”) theories that remain largely untested in this context; and remedies that extend well beyond a monetary payment.
Fit Within DOJ’s Broader Enforcement Priorities
The settlement follows a series of federal policy directives focused on gender-affirming care to minors. Executive Order No. 14187, issued in January 2025 (“EO”), stated that “it is the policy of the United States that it will not fund, sponsor, promote, assist, or support the so-called ‘transition’ of a child from one sex to another.” The EO directed federal agencies to enforce laws that prohibit or restrict such procedures, and also instructed DOJ to prioritize investigations into entities misleading the public about the side effects of gender-affirming care.[1]
In April 2025, DOJ issued a memorandum (“DOJ Memo”) emphasizing that the allegedly illegal provision of gender-affirming care to minors was a DOJ enforcement priority, which would include investigations under the FCA, FDCA, and federal laws prohibiting female genital mutilation targeting providers of pediatric gender-affirming care.[2] Separately, as discussed in a prior Sidley Update, the DOJ Civil Division issued a memorandum in June 2025 which signaled potential FDCA scrutiny of pharmaceutical companies whose drugs are used in connection with gender-transition care.
The TCH resolution is another early indicator of how DOJ intends to operationalize these priorities. The case combines traditional health care fraud tools with policy-driven remedial measures more commonly seen in conduct-focused resolutions. It also shows DOJ’s willingness to coordinate with state attorneys general in areas where state law restricts particular medical services and where Medicaid billing may provide a parallel enforcement hook.
Settlement Terms
Under the terms of the agreements, TCH denied wrongdoing but agreed to pay more than $10 million in damages and civil penalties to resolve allegations that it submitted false billings to payors to secure insurance coverage for gender-affirming services. DOJ alleged that the conduct violated the FCA, FDCA, and other federal fraud and conspiracy laws.[3] The Texas Attorney General’s announcement stated that the settlement addressed alleged billing to Texas Medicaid for “unallowable and illegal” gender-transition services, including through the alleged use of false diagnosis codes.[4]
TCH also agreed to cease providing gender-affirming services to minors and committed to establishing what DOJ described as a first-of-its-kind clinic to provide care to individuals seeking to detransition. In addition, TCH agreed to dedicate additional resources to create a multidisciplinary “detransition” clinic, with services funded by TCH and provided free of charge for the first five years. TCH also agreed to discontinue certain services for minors, including the provision of puberty blockers and “cross-sex” hormones.
The agreement with the Texas Attorney General further requires TCH to terminate five physicians, implement compliance and ethics measures, and amend its bylaws to require automatic relinquishment of privileges for physicians who are deemed to have violated Texas’s prohibition on gender-affirming care to minors.
These non-monetary terms are notable and novel. They suggest that, in future matters involving restricted or prohibited healthcare services, enforcement authorities may seek wider clinical practice, operational and governance restrictions and undertakings in addition to repayment, penalties and other traditional remedial measures.
Key Takeaways
First, the resolution shows how federal and state enforcement theories may converge in areas of policy alignment. Together, DOJ and the Texas Attorney General could leverage the FCA, FDCA, federal fraud and conspiracy laws, billings to Texas Medicaid in alleged violation of Texas law, and Texas restrictions on gender-transition services for minors to put maximum pressure on TCH. Healthcare providers and life sciences companies should therefore review and assess whether their policies, procedures and controls sufficiently account for federal as well as state-by-state restrictions, specifically in areas that intersect with government funded programs and current areas of aligned state and federal enforcement focus.
Second, the non-monetary terms are significant. The announced remedies include the establishment of a first-in-kind clinic, provision free services for a defined period, termination of physician employment and privileges, and bylaw amendments. This suggests that future enforcement resolutions in similar areas may increasingly seek prospective conduct restrictions, governance changes and undertakings aligned to the government’s policy objectives.
Finally, the TCH resolution is not likely to be the end of federal or state enforcement in this area. DOJ has continued to pursue information from other providers through subpoenas, although several courts have narrowed or blocked certain demands for patient information.[5] The EO and DOJ Memo themselves are also subject to various lawsuits challenging their constitutionality and statutory authority.[6] Despite the broader enforcement framework remaining uncertain, the TCH resolution demonstrates DOJ’s willingness to pursue the EO’s goal of restricting gender-affirming care to minors.
Law clerk Micah Stewart also contributed to this article.
[1] Executive Order No. 14187, Protecting Children from Chemical and Surgical Mutilation (Jan. 28, 2025), https://www.whitehouse.gov/presidential-actions/2025/01/protecting-children-from-chemical-and-surgical-mutilation/.
[2] Memorandum for Select Component Heads, Office of the Attorney General, Preventing the Mutilation of American Children (Apr. 22, 025), https://www.justice.gov/ag/media/1402396/dl.
[3] Press Release, Department of Justice, Justice Department Secures Landmark Resolution to End Pediatric “Gender-Affirming Care” and Create Detransition Clinic (May 15, 2026), https://www.justice.gov/opa/pr/justice-department-secures-landmark-resolution-end-pediatric-gender-affirming-care-and.
[4] Press Release, Attorney General of Texas, Attorney General Paxton Makes History by Securing a Landmark Healthcare Fraud Settlement that Creates the Nation’s First-Ever Detransition Clinic and Secures $10 Million from Texas Children’s Hospital for “Transitioning” Kids (May 15, 2026), https://www.texasattorneygeneral.gov/news/releases/attorney-general-paxton-makes-history-securing-landmark-healthcare-fraud-settlement-creates-nations.
[5] Kimberlee Kruesi, Judge blocks Trump administration’s demand for Rhode Island hospital’s records of transgender kids, Associated Press (May 14, 2026), https://apnews.com/article/transgender-youth-medical-records-rhode-island-subpoena-trump-2f5f0e2ba8bdb5913af2195d7bad4b35.
[6] Nate Raymond, US states sue over Trump’s targeting of providers of transgender youth medical care, Reuters (Aug. 1, 2025), https://www.reuters.com/legal/government/us-states-sue-over-trumps-targeting-providers-transgender-youth-medical-care-2025-08-01/; Office of the Attorney General of Washington, In Ninth Circuit argument, Washington defends gender-affirming care against unconstitutional attacks (Mar. 5, 2026), https://www.atg.wa.gov/news/news-releases/ninth-circuit-argument-washington-defends-gender-affirming-care-against.
Civil EnforcementDOJFalse Claims ActFood Drug Cosmetics Act (FDCA)Healthcare
DOJ’s FOCUS Initiative: An Invitation or a Warning to Data Miner Relators? On April 30, 2026, the Department of Justice’s Civil Division announced the Fraud Oversight through Careful Use of Statistics, or FOCUS, initiative. The initiative is aimed at a fast-growing category of False Claims Act relators that exploded in the aftermath of the pandemic and the Paycheck Protection Program: “data miners” who analyze publicly available government data to identify potential fraud and then file qui tam complaints. DOJ’s message to these non-traditional relators is twofold. First, the Department seems to have accepted that data-miner relators are here to stay, and so has invited sophisticated, well-supported data analysis that can help identify fraud that might otherwise go undetected. But second, DOJ intends to prioritize data-miner relators who can demonstrate meaningful pre-filing diligence, analytical rigor, familiarity with the governing program rules, and legally sufficient allegations.